anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Experiments in animal hearts demonstrated that some cases of atrial fibrillation (AF) may be maintained by a small number of drivers in the form of self-sustained, reentrant, electrical impulses located in the posterior left atrium (LA) wall, near the pulmonary veins (PV/LA junction). In those experiments, the fastest rotors acted as the highest frequency drivers that maintained the overall activity. This resulted in a hierarchy of local excitation frequencies throughout both atria. More recently, clinical studies have confirmed the existence of a hierarchical organization in the rate of activation of different regions in the atria of patients with paroxysmal and chronic atrial fibrillation. However, the mechanisms underlying such a hierarchical distribution of frequencies in human AF has not been explored. Our project will try to demonstrate the general hypothesis that both local activation frequency and degree of regularity, while different in different parts of the atrium, are distributed non-randomly, with different patterns of distribution in paroxysmal versus chronic AF patients. We further surmise that such patterns are the result of interrupted propagation of impulses emanating from the drivers localized at the site of highest frequency and organization activity, with a gradual reduction of activation frequency as the distance from the driver increases. To test our hypotheses we will use a combination of clinical and numerical studies. For the clinical part we will gather patients data in a collaborative site at Rochester, NY. The data obtained in that site will be analyzed and interpreted at the Institute for Cardiovascular Research in SUNY Upstate Medical University. For the numerical part, simulations on computer models of AF will be performed solely in the Institute for Cardiovascular Research. Our Specific Aims are: 1. Characterize the frequency of activation during AF in patients after heart surgery and relate it to the presence of fibrosis. 2. In computer simulations, to study the mechanisms of initiation and maintenance of AF at the PV/LA junction using three different computer models with increasing anatomical complexity (the description of the computer simulations is available only in the grant application). Successful achievement of our specific aims should help us advance understanding of the mechanisms and manifestations of this complex arrhythmia and may help to directly improve the efficacy of pharmacological and ablative therapies of AF in patients.
Women recruited for the study will be randomized to the intervention or control groups. Women in the intervention group will be tested in real time for C. trachomatis and Neisseria gonorrhoeae. Patients who test positive for either infection will be linked to physicians at the Center for treatment. For the control group, women will be tested immediately after childbirth or in the event of an adverse pregnancy outcome. In the event of a positive test result, a confirmation test will be run and if positive, the patient will be referred for treatment. The endpoint of the study is defined as either the occurrence of an adverse pregnancy outcome or delivery of a newborn.

Qualitative in-depth interviews will also be conducted with 20 of the women to explore their opinions, attitudes and feedback on the study process. University of North Carolina at Chapel Hill (UNC) investigators will work with the Nanhai Hospital of Southern Medical University and staff at Dermatology Hospital of Southern Medical University to oversee the study.
Use 5/8 in medical needles inject betamethasone 7mg (1ml) in distal wrist crease by sonography- guided. Entering skin with 30 degrees from the ulnar side of palmaris longus tandon. Changing direction of injection to prevent median nerve injury if patients feel numbness or pain in hand.
PURPOSE: To obtain a bone cement composition showing a high maximum tensile deformation, by mixing an acrylic ester monomer with powder of ternary polymer of methyl methacrylate, butyl methacrylate, and styrene. CONSTITUTION: This bone cement composition is prepared by mixing a liquid component (component A) consisting of an acryl ester monomer with a powder component (component B) consisting of a ternary polymer of methyl methacrylate, butyl methacrylate, and styrene in a sterilized state. It is suitable for the component B to contain 55-89.5% of methyl methacrylate to the weight of the component B, 10-40% of butyl methacrylate, and 0.5-5% of styrene. For the component A, it is suitable be blended with a free radical stabilizer such as hydroquinone, etc., and N,N-dimethyl paratoluidine. Deformation of a hardened material of the obtained bone cement composition is measured at 10% of its maximum elongation using an extensometer and its distortion factor is calculated from the elongation at fracture point. Values obtained are shown in the diagram.
PURPOSE:An antihepatitic that contains an extract of SHOMA (Cimicifuga foetida L. var. intermedia Regel) with a specific solvent as an active ingredient. CONSTITUTION:In order to effect efficient removal of foreign matters not related to antihepatitic activity, an extraction solvent selected from n-hexane, ether, benzene, ethyl acetate and chlororform is used to obtain an extract of SHOMA. The exteract is used as an active ingredient to give the objective antihepatitic agent. The extraction of antihepatitic ingredient from SHOMA is acheieved by use of an alcohol or water, however, the extract contains a large amount of foreign materials not relating to antihepatitic activity, and so they are not suitable for extraction. The extraction treatment of the above extract with a specific solvent such as n-hexane gives the objective effective extract.
The invention relates a novel biological polysaccharide, a method for producing the same and application of the same. The biological polysaccharide is prepared by fermenting Streptococcus zooepidemicus CGMCC No. 1988. The preparation method comprises the following process steps of preparation of an inclined plane seed, preparation of seed solution, optimization of fermentation condition, separation purification of products and the like. The biological polysaccharide produced by the method has the advantages of high yield, simple process step, low production cost and the like; and in a liter of fermentation liquid, the content of the polysaccharide is between 20 and 50g, and the whole yield reaches between 70 and 90 percent. The research on the structure and the physical property of the biological polysaccharide shows that the biological polysaccharide comprises a plurality of disaccharide folding structures adopting a connection mode shown in the figure 1, has the characteristics of the macro molecular net structure biological polysaccharide, can be widely applied in various fields such as medical treatment, foods, cosmetics, oil extraction, biological materials and the like, and has important realistic significance.
Intraoperative epidural administration of steroids following discectomy for herniated lumbar disc has been the topic of multiple studies in the literature. The results have been mixed, with the majority of the studies finding some benefit, but outcomes have varied drastically amongst the many studies. The aim of this study is to develop a grading scale for intraoperative assessment of nerve root inflammation to determine if this subjective assessment is an adequate indicator for response to epidural steroids following discectomy. Patients will be allocated randomly preoperatively to the intervention group versus control group. Pictures of the spinal cord and associated nerve root will be captured intraoperatively. These pictures will be scrutinized postoperatively and an inflammation grade will be assigned. The investigators will then identify if nerve roots with a higher-grade of inflammation respond differently to epidural steroid administration when compared to lesser-grades of inflammation. This will be measured with the a variety of outcome measures.
A haemostatic composition is prepared by recovering thrombin from blood plasma, dissolving the thrombin in salt water, adding to the solution a support for thrombin consisting of an amino acid which is soluble in salt water and insoluble in the organic liquids which precipitate thrombin, which absorbs thrombin in a labile manner and which has no detrimental action on parenteral injection, cooling the solution, precipitating both thrombin and the support with an organic liquid, allowing the precipitate to settle in the cold, draining and drying it in vacuo.  Glycocoll is the preferred amino acid, and alcohol or acetone are the preferred precipitating liquids.  The product is used as a haemostatic in general, or particularly for parental intramuscular or oral administration.  The Specification as open to inspection under Sect. 91 also refers to holosides and sugars as suitable supports.  This subject-matter does not appear in the Specification as accepted.
In recent years, with the advancement of cancer treatment techniques and the prolonged survival of patients, the prevalence of Second primary malignancy (SPM) has been escalating, emerging as a significant health issue among cancer survivors. The goal of this study is to identify risk and prognostic factors associated with SPM after first primary kidney cancer and construct nomograms to provide clinical evidence. The main questions this study aims to answer are: (1) What are the risk factors associated with the prevalence of SPM after kidney cancer? (2) What are the prognostic factors associated with the overall survival (OS) of kidney cancer patients with SPM? (3) How to accurately predict the probability of developing SPM after kidney cancer and the OS of kidney cancer patients with SPM? In this retrospective population-based cohort study, Patients diagnosed with first primary kidney cancer between 2000 and 2020 were retrospectively enrolled from the Surveillance, Epidemiology, and End Results (SEER) database. Researchers will concentrate on the risk and prognostic factors of SPM after kidney cancer, and develop nomograms to forecast the development and overall survival (OS) of SPM after kidney cancer.
OBJECTIVE: Increasing evidence indicated that schizophrenia and obesity are associated with altered mitochondrial and immune function. In this study, we investigated the levels of CRP (C-reactive protein) and mitochondrial lymphocytes in chronically treated schizophrenia patients with atypical antipsychotic medications and further explored the relationship between mitochondrial lymphocyte and weight gain as well as cognitive function in these patients.
METHODS: We evaluated the mitochondrial lymphocyte count of 97 patients (53 overweight, 44 non-overweight) and 100 healthy controls using mitochondrial fluorescence staining and flow cytometry (NovoCyte, Agilent Technologies, US). The serum CRP was measured by high-sensitivity enzyme-linked immunosorbent assay (ELISA). Clinical symptoms and cognitive function of the patients were assessed using the Positive and Negative Syndrome Scale (PANSS) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
RESULTS: The results showed that mitochondrial lymphocyte counts of CD3+ T, CD3+CD4+ T, and CD3+CD8+ T cells in schizophrenia patients were higher than in the control group (p < 0.05). Additionally, overweight patients had significantly higher mitochondrial lymphocyte counts of CD3+ T and CD3+CD4+ T cells compared to schizophrenia patients with normal weight. Stratified analysis by gender revealed that there was a statistically significant difference in CD3+CD4+ mitochondrial lymphocyte count in male patients (p = 0.014) and a marginal trend toward significance in female patients (p = 0.058). Furthermore, the mitochondrial lymphocyte counts of CD3+ T and CD3+CD4+ T cells, as well as CRP levels, were positively correlated with BMI in schizophrenia patients, but the mitochondrial lymphocyte counts of CD3+CD4+ T cells were negatively correlated with the language scale in the RBANS.
CONCLUSION: Our study results provide evidence for the association between altered mitochondrial T lymphocyte and weight gain as well as cognitive impairment in schizophrenia patients treated with atypical antipsychotic medications.
OBJECTIVES: I. Determine the median time to progression, median survival, and objective response of patients with anaplastic astrocytoma or anaplastic oligoastrocytoma in first relapse treated with intravenous leflunomide (SU101). II. Assess the safety of SU101 in these patients. III. Describe the health-related quality of life of patients treated with intravenous SU101.

OUTLINE: This is an open label, multicenter study. Patients receive leflunomide (SU101) IV over 6 hours on days 1-4. Patients then receive SU101 IV over 6 hours weekly for 6 weeks (beginning between days 8-12). Patients exhibiting complete response, partial response, or stable disease may continue on treatment for up to a year or until disease progression or unacceptable toxicity occurs. Patients continuing therapy receive SU101 IV over 6 hours every week for 7 weeks, followed by 1 week of rest. Quality of life is assessed every 8 weeks and at the end of the study. Patients are followed every 8 weeks or until tumor progression.

PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
Cutaneous candidiasis, tinea corporis, tinea cruris, tinea pedis and tinea (pityriasis) versicolor: It is recommended that Ketoconazole Cream 2% be applied once daily to cover the affected and immediate surrounding area. Clinical improvement may be seen fairly soon after treatment is begun; however, candidal infections and tinea cruris and corporis should be treated for two weeks in order to reduce the possibility of recurrence. Patients with tinea versicolor usually require two weeks of treatment. Patients with tinea pedis require six weeks of treatment. Seborrheic dermatitis: Ketoconazole Cream 2% should be applied to the affected area twice daily for four weeks or until clinical clearing.

If a patient shows no clinical improvement after the treatment period, the diagnosis should be redetermined.
ABSTRACT This discovery resulted when a .lambda. gtll cDNA library of normal human melanocytes were screened with antibodies directed against purified hamster tyrosinase.  Sixteen independent clones which gave a positive signal were isolated from 5 x 105 independent plaques.  cDNA inserts of 13 clones among the 16 candidates cross-hybridized with each other, indicating that they were from related mRNA species.  mRNA homologous to a representative cDNA .lambda. mel 34 was expressed specifically in melanocytes, detecting an approximately 2.4 kb mRNA species of human melanocytes.  The nucleotide sequence of the three overlapping cDNA inserts spanning 1.88 kb was determined and an amino acid sequence was deduced.  The human tyrosinase is composed of 548 amino acids with a molecular weight of 62,160 excluding a hydrophobic signal peptide. Mouse genomic DNA blot analysis revealed that the gene for mel 34 was deleted in albino mouse homozygous for the deletion at and around  the albino locus on chromosone 7.  It is concluded that A mel 34 contained cDNA encoding human tyrosinase.  Moreover, the cDNA gene for human tyrosinase was recovered from the .lambda. mel 34 and can be used for many purposes including the production of pure human tyrosinase.     In addition, the three clones of the 11 not represented by .lambda. mel 34 are represented by .lambda. mel 17-1.  The gene for  .lambda.mel 17-1 cDNA was not mapped at the albino locus, detected single hybridizing restriction fragment in human and mouse DNA, and was highly conserved from mouse to human. The abundance of .lambda. mel 17-1 cRNA paralleled the melanin content in human and mouse melanocytes.  The expression of .lambda. mel 17-1 cRNA was elevated after stimulation of mouse and human melanoma cells with MSH or/and IBMX, and U-V light (such as suntan).  This was also closely correlated with the elevation of melanin content.  The fact that the .lambda. mel 17-1 gene is conserved evolutionarily indicates that the molecule encoded by the .lambda. mel 17-1 has biologiacally important functions.            The expression of that gene is controlled by hormones (MSH) or U-V light and positively correlated with the melanin content. These data indicate that the gene is involved in melanin biosynthesis in addition to tyrosinase.  Current studies suggest that .lambda. mel 17-1 gene product act on melanin biosynthesis's pathway distal to tyrosinase.
Device: Direct Cortical Stimulation. 150 stimulations with stimulations lasting 5 seconds at different target electrodes at two target frequencies (e.g. 5 Hz and 10 Hz) 2 milliampere in amplitude (Pulse shape - Biphasic square pulse 200 microsecond in duration per phase). Stimulation will be applied concurrently with the task and stimulation trials will be randomly interleaved with sham trials.
<P>PROBLEM TO BE SOLVED: To enable a patient to continue medical treatment in the medical treatment using a vacuum impregnation apparatus for growing and restoring hairs by allowing the treatment to have no malpractice.  <P>SOLUTION: The remote medical treatment supporting system of the vacuum impregnation apparatus for growing and restoring hairs is provided with a data administration server 10 for storing a medical sheet on the Internet and a file server 12 for storing control data of the vacuum impregnation apparatus 20. A patient 2 accesses the data administration server 10, observing the medical sheet renewed by a doctor 3, downloading the control data from the file server 12 to have the medical treatment using the vacuum impregnation apparatus 20 and uploading the result. The doctor 3 observes and medically checks up the uploaded medical sheet to upload the medical sheet written on a treatment plan into the data administration server 10 and writes the control data based on the medical sheet to upload the control data into the file server 12. The medical treatment using a network and having the medical checkup by the doctor 3 achieves effects while the treatment has no malpractice. Thereby the treatment can be continued.  <P>COPYRIGHT: (C)2004,JPO
INTRODUTION: According to the European Position Paper on Rhinosinusitis and Nasal Polyps 2012, chronic rhinosinusitis in adults can be defined as an inflammation of the nasal mucosa and paranasal sinuses lasting 12 weeks or more , associated or not with nasal polyposis. As to the origin of the polyps, these are typically related to the eosinophilic inflammation of the upper airways and result in obstructions in different degrees of the nasal cavities. Maximum clinical treatment - a combination of several classes of drugs to optimize therapy - often proves to be the first choice in the management of this disease. There is, however, no consensus on the composition or duration of maximal clinical treatment, and success rates are extremely variable. If there is no improvement in the condition, surgical treatment is usually instituted and, if necessary, supplemented with topical post-operative treatment. Recent studies have led to the perception that sprays and aerosols can not adequately reach the paranasal sinuses resulting in a better effect of the medication, if possible, such methods should be replaced by nasal cavity lavages using high volume solutions. OBJECTIVES: The present study aims to compare, through validated tests, the impact of the inclusion of nasal lavage with budesonide diluted in high volume in relation to placebo, in the improvement of the symptoms, signs, and quality of life of patients with chronic rhinosinusitis with polyposis. If effective, this therapy may decrease surgical indications and, consequently, health expenditures for the government. METHODOLOGY: Parallel, randomized, placebo-controlled, parallel type clinical trial. Patients with chronic rhinosinusitis with polyposis will be divided randomly with stratification for the presence of asthma in two groups (two blocks of 30 patients, 9 asthmatics each). It will evaluate the effectiveness of nasal lavage with 2mg budesonide diluted in high volume daily added to the initial systemic corticosteroid injectable and the topic for 16 weeks compared to placebo. EXPECTED RESULTS: It is expected that diluted budesonide improvement in the symptoms, signs, and quality of life of patients with chronic rhinosinusitis with polyposis.
Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg SC injection Q2W, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
Amplibody compositions and methods used to interact with agglomeration proteins are disclosed herein. Compositions herein comprise one or more DNA or RNA molecules having affinity for at least one agglomeration protein. The nucleic acid component is a naturally or non-naturally occuring molecule with twenty or more ribonucleotide bases. For RNA, at least one nucleotide sequence portion of this RNA molecule has affinity to at least one consensus sequence present in the agglomeration RNA-binding protein. The portion of nucleotide sequence of RNA having affinity for agglomeration proteins is a sequence that is derived from either and RNA virus, and RNA agglomeration proteins is a sequence that is derived from either and RNA virus, an RNA phage, a messenger RNA (“mRNA”), a ribosomal RNA (“rRNA), a transfer RNA (“tRNA”), a sequence that is received as a template by one or more RNA dependent RNA polymerases, or a combination thereof. Methods disclosed herein are directed towards detecting the presence of one or more agglomeration proteins in a sample matrix using the amplibody compositions described herein.
In some embodiments, the present disclosure pertains to methods of treating an inflammatory disease in a subject by administering a carbon material to the subject. In some embodiments, the carbon material selectively targets T cells in the subject. In some embodiments, the carbon material includes poly(ethylene glycol) -functionalized hydrophilic carbon clusters. In some embodiments, the administration of the carbon material to the subject reduces or inhibits T cell-mediated reactions in the subject. In some embodiments, the carbon material selectively targets T cells over other types of immune cells by preferential uptake into the T cells. In some embodiments, the carbon material reduces or inhibits proliferation of targeted T cells, reduces or inhibits cytokine production by targeted T cells, and reduces intracellular oxidant content in targeted T cells. In some embodiments, the present disclosure pertains to methods of modulating T cells ex-vivo by incubating the T cells with a carbon material.
This proposal will investigate the effect of the newly anti-adhesive agent 4DryField. Stoma creation is common in complicated colorectal disease. Hartman procedure (End colostomy) is used in patients advanced rectal cancer or severe diverticulitis. Loop colostomy or ileostomy is used in patients need stool diversion for prevent leakage related infection.

4DryField is a powder consisting of sterile hydrophilic microparticles, which is anufactured from highly purified potato starch in a complex process. A unique starch-based medical device is 4DryField® PH (4DryField; PlantTec Medical GmbH, Germany) as it is the only product proven to provide hemostasis and prevent the formation of adhesions. In rat model, the 4DryField acheieve the significant adhesion prevention effectiveness. In gynecologic surgery, 4DryField showed effective adhesion prevention as confirmed at second look laparoscopy. The gel is easilier to applied in the uneven surface of pelvic cavity and peristomy area than other manufacture. The indication of adhesion prevention is approved by TFDA.